BELLUS Health to Present at Jefferies Global Healthcare Conference in London

BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (BELLUS Health or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company on Wednesday, November 20, 2019 at the Jefferies Global Healthcare Conference in London.

Metadata
Provider: 
Business Wire, Inc.
Retrieved on: 
Wednesday, November 13, 2019
Information
Tags: 
Biotechnology, General Health, Health, Pharmaceutical, Clinical trials, Chronic cough, Cough, Chronic condition
Geotags: 
QUEBEC, Canada
⚠ generated by AI ↴
Organisation: 
BELLUS HEALTH
Summary
Key Points: 
  • BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (BELLUS Health or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company on Wednesday, November 20, 2019 at the Jefferies Global Healthcare Conference in London.
  • A live webcast may be accessed on the Events and Presentations page under the Investors & News section of BELLUS Health's website at www.bellushealth.com .
  • BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders.
  • The Companys product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.


BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company on Wednesday, November 20, 2019 at the Jefferies Global Healthcare Conference in London.

Presentation Details:

Event: Jefferies Global Healthcare Conference in London

Date/Time: Wednesday, November 20, 2019 at 9:20 a.m. GMT

Location: London

A live webcast may be accessed on the Events and Presentations page under the Investors & News section of BELLUS Health's website at www.bellushealth.com. Following the event, an archived webcast and presentation will be available on the Company’s website.

About BELLUS Health

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.

Copyright: 
Copyright Business Wire 2019